LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals Inc (LBRX) Stock Price, Analysis & Data
| Bid | 32.42 |
| Market Cap | 1.3B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -85.69M |
| Beta | n/a |
| EPS (ttm) | -5.1 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.17 |
| P/B (ttm) | 3.44 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 57.43 |
| Volume | 299,885 |
| Avg. Volume (20D) | 307,109 |
| Open | 45.32 |
| Previous Close | 45.33 |
| Day's Range | 44.03 - 46.01 |
| 52-Week Range | 13.36 - 49.14 |
| Analyst | Strong Buy |
| Price Target | 42.5 (-6.35%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for...
Financial Performance
In 2025, LB Pharmaceuticals Inc's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -25.2M, a decrease of -60.06%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for LBRX stock is "Strong Buy". The 12-month stock price forecast is 42.5, which is downside of 6.35% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
